- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | GENETIC SIGNATURES LIMITED: Ceasing to be a substantial holder | - | ASX | ||
| Mi | Health Check: Genetic Signatures and Microba talk merger as BCAL crashes the romance | 1 | Stockhead | ||
| GENETIC SIGNATURES Aktie jetzt für 0€ handeln | |||||
| Mi | Genetic Signatures FY2026 slides: losses narrow despite revenue decline | 1 | Investing.com | ||
| Mi | GENETIC SIGNATURES LIMITED: Genetic Signatures and Microba in Merger Discussions | 3 | ASX | ||
| Mi | BCAL DIAGNOSTICS LIMITED: BCAL Takes Interest in Genetic Signatures to 18.46% | - | ASX | ||
| Mi | GENETIC SIGNATURES LIMITED: Change in Substantial Shareholder Notice from BDX | 1 | ASX | ||
| Di | GENETIC SIGNATURES LIMITED: Change in substantial holding | 1 | ASX | ||
| Di | GENETIC SIGNATURES LIMITED: FY26 Appendix 4G and Corporate Governance Statement | 3 | ASX | ||
| Di | GENETIC SIGNATURES LIMITED: FY26 Market Update | 1 | ASX | ||
| Di | GENETIC SIGNATURES LIMITED: FY26 Results Release | 1 | ASX | ||
| Di | GENETIC SIGNATURES LIMITED: FY26 Appendix 4E and Annual Report | 1 | ASX | ||
| Mo | GENETIC SIGNATURES LIMITED: FY 26 Annual Results and Investor Webinar Notification | 1 | ASX | ||
| 21.08. | GENETIC SIGNATURES LIMITED: Commercial Testing Commences at Hvidovre Hospital in Denmark | 2 | ASX | ||
| 23.07. | GENETIC SIGNATURES LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 02.07. | GENETIC SIGNATURES LIMITED: Becoming a substantial holder from BDX | - | ASX | ||
| 02.07. | GENETIC SIGNATURES LIMITED: GSS responds to the BCAL Diagnostics Announcement | - | ASX | ||
| 02.07. | BCAL Diagnostics Secures Strategic Stake in Genetic Signatures | 1 | Finance News Network | ||
| 02.07. | GENETIC SIGNATURES LIMITED: BDX: BCAL to Acquire Shares in Genetic Signatures | - | ASX | ||
| 02.07. | BCAL DIAGNOSTICS LIMITED: BCAL to Acquire Shares in Genetic Signatures | - | ASX | ||
| 01.07. | GENETIC SIGNATURES LIMITED: Ceasing to be a substantial holder | - | ASX |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 13,730 | 0,00 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| BIONTECH | 88,30 | +0,11 % | Zahlen stark, Bewertung billig: Zwar nicht BioNTech oder Moderna, aber auch dieses Unternehmen hat geliefert! | © Foto: Google GeminiZuletzt sorgten vor allem Biotechnologie-Werte für Schlagzeilen, doch auch klassische Pharmaunternehmen wie Dermapharm befinden sich in einer guten Verfassung Enthaltene Werte:... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | DAX Verlierer: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| ARCUTIS BIOTHERAPEUTICS | 23,780 | 0,00 % | Here's Why You Should Add ARQT Stock to Your Portfolio Now | ||
| HARMONY BIOSCIENCES | 39,210 | 0,00 % | Wolfe Research initiates Harmony Biosciences stock at Outperform | ||
| ERASCA | 18,040 | +0,06 % | Erasca, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,97 | 0,00 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,670 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Merck, Vidac Pharma, Moderna - Neue Krebswaffen elektrisieren die Börse | Ein Durchbruch in der Krebsforschung versetzte die Börse in der vergangenen Woche in Euphorie. Eine personalisierte mRNA-Therapie hat erstmals in einer großen Phase-3-Studie entscheidende Ziele erreicht... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 345,01 | +0,08 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,760 | -0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,08 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,210 | +0,06 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 23,370 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6- month interim analysis and FDA feedback on the BLA... ► Artikel lesen |
Das Unternehmen GENETIC SIGNATURES LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENETIC SIGNATURES LIMITED finden Sie auf Wallstreet Online.